Vanguard Group Incs Strategic Acquisition in Atara Biotherapeutics Inc
ATRA Stock | USD 13.33 1.13 9.26% |
About 57% of all Atara Biotherapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Atara Biotherapeutics suggests that some traders are interested. The current market sentiment, together with Atara Biotherapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Atara Biotherapeutics stock news signals to limit their universe of possible portfolio assets.
Atara |
Overview of Vanguards Recent Transaction On September 30, 2024, Vanguard Group Inc made a notable addition to its investment portfolio by acquiring 180,715 sha
Read at gurufocus.com
Atara Biotherapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Atara Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Atara Biotherapeutics Fundamental Analysis
We analyze Atara Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atara Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atara Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Atara Biotherapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Atara Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Atara Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Atara Biotherapeutics could also be used in its relative valuation, which is a method of valuing Atara Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Atara Biotherapeutics Related Equities
MREO | Mereo BioPharma | 12.39 | ||||
SANA | Sana Biotechnology | 7.36 | ||||
ALLO | Allogene Therapeutics | 7.18 | ||||
BTAI | BioXcel Therapeutics | 2.94 | ||||
ITOS | Iteos Therapeutics | 1.63 | ||||
ABOS | Acumen Pharmaceuticals | 1.13 | ||||
APLS | Apellis Pharmaceuticals | 0.33 | ||||
RCUS | Arcus Biosciences | 0.31 | ||||
FATE | Fate Therapeutics | 1.19 | ||||
HRTX | Heron Therapeuti | 1.25 | ||||
KPTI | Karyopharm Therapeutics | 3.23 | ||||
TCRX | Tscan Therapeutics | 3.32 | ||||
XFOR | X4 Pharmaceuticals | 4.92 | ||||
CRBU | Caribou Biosciences | 5.59 | ||||
HOOK | Hookipa Pharma | 6.40 |
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |